The Obesity Action Coalition and the Obesity Care Advocacy Network made a step-by-step roadmap for people trying to get GLP-1 coverage through the Medicare program.
Recap by typeshit. Post by Facebook on Facebook.
The two drugs brought in $14.9 billion of Lilly's $23.0 billion fiscal Q2 revenue while US prices fell 9%, Trefis says. The Q3 report is expected around October 29.
Novo Nordisk is lowering what Wegovy costs in China, a fresh move in the race for the country's obesity drug market. No figures were given.
Hanmi set Eppe's first four weeks at 129,800 won ahead of a late-month launch, while Novo seeks Korean insurance coverage for Wegovy in high-risk patients.
Novo trades near 11.8 times forward earnings against an 18.6 average, and the piece asks whether that makes it a buying chance or a value trap.
The post says four in ten patients drop GLP-1 drugs within a year over side effects, and pharma is turning to amylin-based shots as the next step.
Medical Xpress reports late stage results for Lilly's triple-action shot in patients with type 2 diabetes.
Loading…